What are the opportunities and challenges of using alternative clinical endpoints? How can alternative endpoints help improve the lives of patients? These are the topics of the breakfast meeting hosted by Oslo Economics and Bristol Myers Squibb on November 27 at the Norwegian Cancer Society’s Science Center.
Alternative clinical endpoints are increasingly used to assess the effectiveness of new treatments. These endpoints allow for earlier evaluation of treatment effects and facilitate faster access to innovative therapies for patients. Although alternative endpoints often involve uncertainty, they provide an earlier indication of a treatment’s effectiveness compared to traditional outcome measures.
At the breakfast meeting, we will present our new report, which examines the value of alternative measures of treatment effect. Erik Magnus Sæther will discuss the opportunities and challenges associated with the use of alternative endpoints. We will also hear from several other key figures, including Terje Rootwelt, Einar Andreassen, Ali Areffard, Sigrid Bratlie, Anne Marie Holck Storås, and more.
We hope you will join us for this important discussion!
More information and registration for the breakfast meeting can be found here.
